Kubota Pharmaceutical Holdings Co.,Ltd. [4596.T]
TOKYO, Mar 27 (Pulse News Wire) – Kubota Pharmaceutical Holdings CO.,LTD. (4596.T) aims to capture approximately ¥1 billion of the estimated €¥750 million European market for its Starry Night disease treatment candidate drug.
The company projects a total addressable market of around €¥3.1 billion, with a serviceable obtainable market of roughly €¥1 billion. Additionally, Kubota targets the proliferative diabetic retinopathy treatment market, estimating a TAM of $1.71 billion across major regions. It plans to secure a share of the Alzheimer's disease treatment market, which could reach up to $7.6 billion by targeting key countries such as the US, EU nations, and Japan.
In parallel, Kubota continues to develop wearable devices like Kubota Glass® for myopia correction and eyeMO® for remote ophthalmic care, aiming to capitalize on growing demand in markets like China and Europe. The company’s revenue model includes royalties based on net sales and manufacturing support fees for pharmaceutical products, alongside flexible pricing models for medical devices. Kubota faces risks including regulatory delays and potential side effects during clinical trials, but has strategies in place to mitigate these challenges through partnerships and diversified project pipelines.
🟡 Confidence: Standard AI-translated content.